<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Hepatitis B virus (HBV) reactivation induced by bortezomib use and autologous bone marrow transplantation in a patient recovered from HBV infection

dc.contributor.coauthorYılmaz-Karadağ, Fatma
dc.contributor.coauthorErgen, Pınar
dc.contributor.coauthorAydın, Özlem
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.facultymemberNo
dc.contributor.kuauthorÖztürk, Erman
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.date.accessioned2024-11-09T23:57:43Z
dc.date.issued2017
dc.description.abstractIn hematologic malignancy patients with HBsAg positivity, the risk of hepatitis B reactivation is high in cases of high dose use of corticosteroids, rituximab, chemotherapy agents belonging to the anthracycline group and stem cell transplantation. HBV reactivation has been reported in the literature generally in HBsAgnegative, anti-HBc IgG- and anti-HBs-positive lymphoma patients in case of stem cell transplantation or use of rituximab as a chemotherapeutic agent. There are publications that report cases of HBV reactivation in HBsAg-negative multiple myeloma patients who have recieved bortezomib and/or stem cell. In this article, we present a multiple myeloma case with full recovery from HBV infection developing an acute hepatitis due to HBV reactivation after bortezomib use and autologous bone marrow transplantation. Finally, it was successfully treated with lamivudine. It is aimed to draw attention to the fact that hepatitis B serologic markers should be closely monitored for possibility of reactivation of hepatitis in candidates of chemotherapy/stem cell transplantation recovering from HBV infection.
dc.description.fulltextYes
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyTRDizin
dc.description.openaccessDiamond OA
dc.description.peerreviewstatusN/A
dc.description.publisherscopeNational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.description.studentonlypublicationNo
dc.description.studentpublicationNo
dc.description.versionPublished Version
dc.identifier.WoSQuartileQ3
dc.identifier.doi10.5152/kd.2017.35
dc.identifier.eissn1309-1484
dc.identifier.embargoNo
dc.identifier.endpage54
dc.identifier.filenameinventorynoIR07583
dc.identifier.issn1301-143X
dc.identifier.issue3
dc.identifier.scopus2-s2.0-85038862716
dc.identifier.startpage52
dc.identifier.urihttps://doi.org/10.5152/kd.2017.35
dc.identifier.urihttps://hdl.handle.net/20.500.14288/15346
dc.identifier.volume30
dc.identifier.wos000419259100010
dc.keywordsHepatitis B virus reactivation
dc.keywordsMultiple myeloma
dc.keywordsBortezomib
dc.keywordsHematopoietic stem cell transplantation
dc.language.isotur
dc.publisherDOC Design Informatics
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofKlimik Journal
dc.relation.openaccessYes
dc.rightsCC BY-NC (Attribution-NonCommercial)
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectMicrobiology
dc.titleHepatitis B virus (HBV) reactivation induced by bortezomib use and autologous bone marrow transplantation in a patient recovered from HBV infection
dc.title.alternativeHepatit B virüsü (HBV) infeksiyonu geçirmiş hastada bortezomib kullanımı ve otolog kemik iliği nakli sonrası gelişen HBV reaktivasyonu
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorÖztürk, Erman
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
IR07583.pdf
Size:
48.94 KB
Format:
Adobe Portable Document Format